Do, Mai 16th 2024
Novartis surpasses minimum acceptance threshold in its bid to acquire Morphosys, paving the way for full integration and enhanced drug development capabilities.
Novartis can definitely take over the German biotech company Morphosys. The Basel-based pharmaceutical company has exceeded the necessary minimum acceptance threshold.
By the end of the acceptance period on May 13, the offer had been accepted by around 79.6 percent of Morphosys’ total share capital, according to a statement issued on Thursday. All conditions, including the minimum acceptance threshold of 65 percent, have thus been met.
The statutory two-week extension period for acceptance of the offer begins on Friday (tomorrow) and lasts until May 30 (midnight). During this period, Morphosys shareholders who have not yet tendered their shares can accept the offer.
Now that the offer conditions have been met, the necessary steps for the integration of Morphosys can also be taken forward, Novartis states. In particular, the Basel-based company will gain full access to pelabresib (CPI-0610), a novel compound used in combination in patients with myelofibrosis.
Novartis announced its takeover plans at the beginning of February, offering Morphosys shareholders 68 euros per share. The total price thus amounts to around 2.7 billion euros.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic 
